# PeptideScanner evidence objects: Lutetium Lu 177 dotatate

Every published version of the records placed with Lutetium Lu 177 dotatate, one section per evidence object. The section anchor is the object's path id; the JSON twin is https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json. Selected public evidence only; not medical advice.

- Objects: 42
- Manifest: https://peptidescanner.com/evidence/v1/manifest.json

---

<a id="clinicaltrials-gov-nct01578239-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT01578239

> PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct01578239-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-04-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct01578239-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct01578239-lutetium-lu-177-dotatate-v1
- Content SHA-256: `ef6ef7d75bf64d568e268cb39a41e952a0f16aab0e4bb9911875c32672c2a3b5`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT01578239 ([`ctg-observation-nct01578239-2022-04-04-b08cad65131f`](#source-ctg-observation-nct01578239-2022-04-04-b08cad65131f))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct01578239-2022-04-04-b08cad65131f`](#source-ctg-observation-nct01578239-2022-04-04-b08cad65131f))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT01578239 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-04-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct01578239-2022-04-04-b08cad65131f`](#source-ctg-observation-nct01578239-2022-04-04-b08cad65131f))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct01578239-2022-04-04-b08cad65131f`](#source-ctg-observation-nct01578239-2022-04-04-b08cad65131f))

### Sources

<a id="source-ctg-observation-nct01578239-2022-04-04-b08cad65131f"></a>
- **ClinicalTrials.gov record NCT01578239 · retained source version 2022-04-04:b08cad65131f7446cbd4446a39ce21372a048a3d0f973a2f56cf98c56c018aad** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT01578239) (`ctg-observation-nct01578239-2022-04-04-b08cad65131f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT01578239." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct01578239-lutetium-lu-177-dotatate-v1 SHA-256: ef6ef7d75bf64d568e268cb39a41e952a0f16aab0e4bb9911875c32672c2a3b5.

---

<a id="clinicaltrials-gov-nct03325816-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03325816

> PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03325816-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2021-03-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03325816-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03325816-lutetium-lu-177-dotatate-v1
- Content SHA-256: `d03cd7aff9a16c3e1e51a559646686d006d52fdccea0b1040388944f04c94e7a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03325816 ([`ctg-observation-nct03325816-2021-03-16-a4b650616208`](#source-ctg-observation-nct03325816-2021-03-16-a4b650616208))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03325816-2021-03-16-a4b650616208`](#source-ctg-observation-nct03325816-2021-03-16-a4b650616208))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03325816 at 2026-11-16T01:36:36.861Z. Its registry update date was 2021-03-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03325816-2021-03-16-a4b650616208`](#source-ctg-observation-nct03325816-2021-03-16-a4b650616208))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03325816-2021-03-16-a4b650616208`](#source-ctg-observation-nct03325816-2021-03-16-a4b650616208))

### Sources

<a id="source-ctg-observation-nct03325816-2021-03-16-a4b650616208"></a>
- **ClinicalTrials.gov record NCT03325816 · retained source version 2021-03-16:a4b65061620827d5f1b0bd395851ceb5497477231aa28fce596e8b32e99dfe3c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03325816) (`ctg-observation-nct03325816-2021-03-16-a4b650616208`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03325816." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03325816-lutetium-lu-177-dotatate-v1 SHA-256: d03cd7aff9a16c3e1e51a559646686d006d52fdccea0b1040388944f04c94e7a.

---

<a id="clinicaltrials-gov-nct03457948-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03457948

> PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03457948-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-28
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03457948-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03457948-lutetium-lu-177-dotatate-v1
- Content SHA-256: `0aaec3288b739dcbb9ace84ee47d6d9e0d4a930d0ccb16fee2370499438ff903`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03457948 ([`ctg-observation-nct03457948-2026-08-28-a06027fc2e9e`](#source-ctg-observation-nct03457948-2026-08-28-a06027fc2e9e))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03457948-2026-08-28-a06027fc2e9e`](#source-ctg-observation-nct03457948-2026-08-28-a06027fc2e9e))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03457948 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-28, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03457948-2026-08-28-a06027fc2e9e`](#source-ctg-observation-nct03457948-2026-08-28-a06027fc2e9e))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03457948-2026-08-28-a06027fc2e9e`](#source-ctg-observation-nct03457948-2026-08-28-a06027fc2e9e))

### Sources

<a id="source-ctg-observation-nct03457948-2026-08-28-a06027fc2e9e"></a>
- **ClinicalTrials.gov record NCT03457948 · retained source version 2026-08-28:a06027fc2e9e0a227b10ba60f686b6716907436e3c68329dadc0a2720ce759fe** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03457948) (`ctg-observation-nct03457948-2026-08-28-a06027fc2e9e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03457948." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03457948-lutetium-lu-177-dotatate-v1 SHA-256: 0aaec3288b739dcbb9ace84ee47d6d9e0d4a930d0ccb16fee2370499438ff903.

---

<a id="clinicaltrials-gov-nct03590119-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03590119

> PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03590119-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2022-11-08
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03590119-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03590119-lutetium-lu-177-dotatate-v1
- Content SHA-256: `d2d10711963259ca6b88713456905eca754a623b26e41af4d1e58fd6d6dbd38e`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03590119 ([`ctg-observation-nct03590119-2022-11-08-d396cb5c0165`](#source-ctg-observation-nct03590119-2022-11-08-d396cb5c0165))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03590119-2022-11-08-d396cb5c0165`](#source-ctg-observation-nct03590119-2022-11-08-d396cb5c0165))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03590119 at 2026-11-16T01:36:36.861Z. Its registry update date was 2022-11-08, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03590119-2022-11-08-d396cb5c0165`](#source-ctg-observation-nct03590119-2022-11-08-d396cb5c0165))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03590119-2022-11-08-d396cb5c0165`](#source-ctg-observation-nct03590119-2022-11-08-d396cb5c0165))

### Sources

<a id="source-ctg-observation-nct03590119-2022-11-08-d396cb5c0165"></a>
- **ClinicalTrials.gov record NCT03590119 · retained source version 2022-11-08:d396cb5c0165dda5b26bfe44088f563a6da46e5914da30fe301af952ea8a1c65** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03590119) (`ctg-observation-nct03590119-2022-11-08-d396cb5c0165`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03590119." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03590119-lutetium-lu-177-dotatate-v1 SHA-256: d2d10711963259ca6b88713456905eca754a623b26e41af4d1e58fd6d6dbd38e.

---

<a id="clinicaltrials-gov-nct03971461-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03971461

> PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03971461-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-29
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03971461-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03971461-lutetium-lu-177-dotatate-v1
- Content SHA-256: `08cc757d464aa9e50890b40abb92e89af796d257538da3e0c90aacc28f5f3191`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03971461 ([`ctg-observation-nct03971461-2026-09-29-9e40665ac983`](#source-ctg-observation-nct03971461-2026-09-29-9e40665ac983))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03971461-2026-09-29-9e40665ac983`](#source-ctg-observation-nct03971461-2026-09-29-9e40665ac983))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03971461 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-29, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03971461-2026-09-29-9e40665ac983`](#source-ctg-observation-nct03971461-2026-09-29-9e40665ac983))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03971461-2026-09-29-9e40665ac983`](#source-ctg-observation-nct03971461-2026-09-29-9e40665ac983))

### Sources

<a id="source-ctg-observation-nct03971461-2026-09-29-9e40665ac983"></a>
- **ClinicalTrials.gov record NCT03971461 · retained source version 2026-09-29:9e40665ac98331af291b04dca01f38b241b928fe836241c7f2066ae86b15a45b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03971461) (`ctg-observation-nct03971461-2026-09-29-9e40665ac983`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03971461." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03971461-lutetium-lu-177-dotatate-v1 SHA-256: 08cc757d464aa9e50890b40abb92e89af796d257538da3e0c90aacc28f5f3191.

---

<a id="clinicaltrials-gov-nct03972488-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT03972488

> PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct03972488-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-01-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct03972488-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03972488-lutetium-lu-177-dotatate-v1
- Content SHA-256: `83309763899068bc0f59daed86a3cdd9e4b2f52eb7a655d316ac14b7b9660737`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT03972488 ([`ctg-observation-nct03972488-2026-01-21-0cd0880f7e20`](#source-ctg-observation-nct03972488-2026-01-21-0cd0880f7e20))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03972488-2026-01-21-0cd0880f7e20`](#source-ctg-observation-nct03972488-2026-01-21-0cd0880f7e20))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT03972488 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-01-21, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct03972488-2026-01-21-0cd0880f7e20`](#source-ctg-observation-nct03972488-2026-01-21-0cd0880f7e20))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct03972488-2026-01-21-0cd0880f7e20`](#source-ctg-observation-nct03972488-2026-01-21-0cd0880f7e20))

### Sources

<a id="source-ctg-observation-nct03972488-2026-01-21-0cd0880f7e20"></a>
- **ClinicalTrials.gov record NCT03972488 · retained source version 2026-01-21:0cd0880f7e20d1d83deaa01e1bcba549c35befdb8792fb964d714551b9e2b554** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT03972488) (`ctg-observation-nct03972488-2026-01-21-0cd0880f7e20`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT03972488." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct03972488-lutetium-lu-177-dotatate-v1 SHA-256: 83309763899068bc0f59daed86a3cdd9e4b2f52eb7a655d316ac14b7b9660737.

---

<a id="clinicaltrials-gov-nct04082520-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04082520

> PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04082520-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04082520-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04082520-lutetium-lu-177-dotatate-v1
- Content SHA-256: `af4996fa72f5d6bac55c2f0868b564da363d924fce9fc3bb7a7b0f77deb0836d`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04082520 ([`ctg-observation-nct04082520-2026-10-13-43632512968b`](#source-ctg-observation-nct04082520-2026-10-13-43632512968b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04082520-2026-10-13-43632512968b`](#source-ctg-observation-nct04082520-2026-10-13-43632512968b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04082520 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04082520-2026-10-13-43632512968b`](#source-ctg-observation-nct04082520-2026-10-13-43632512968b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04082520-2026-10-13-43632512968b`](#source-ctg-observation-nct04082520-2026-10-13-43632512968b))

### Sources

<a id="source-ctg-observation-nct04082520-2026-10-13-43632512968b"></a>
- **ClinicalTrials.gov record NCT04082520 · retained source version 2026-10-13:43632512968b57cf9f7746814a7bef1f3430095db4ab05d4a2257cc6c60c331a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04082520) (`ctg-observation-nct04082520-2026-10-13-43632512968b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04082520." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04082520-lutetium-lu-177-dotatate-v1 SHA-256: af4996fa72f5d6bac55c2f0868b564da363d924fce9fc3bb7a7b0f77deb0836d.

---

<a id="clinicaltrials-gov-nct04234568-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04234568

> PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04234568-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-13
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04234568-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04234568-lutetium-lu-177-dotatate-v1
- Content SHA-256: `03f7b97ceb713fd11f52135a31a86684782f1cd87292236a9848bc9902a617ba`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04234568 ([`ctg-observation-nct04234568-2026-11-13-a28e8c0c7234`](#source-ctg-observation-nct04234568-2026-11-13-a28e8c0c7234))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04234568-2026-11-13-a28e8c0c7234`](#source-ctg-observation-nct04234568-2026-11-13-a28e8c0c7234))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04234568 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-13, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04234568-2026-11-13-a28e8c0c7234`](#source-ctg-observation-nct04234568-2026-11-13-a28e8c0c7234))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04234568-2026-11-13-a28e8c0c7234`](#source-ctg-observation-nct04234568-2026-11-13-a28e8c0c7234))

### Sources

<a id="source-ctg-observation-nct04234568-2026-11-13-a28e8c0c7234"></a>
- **ClinicalTrials.gov record NCT04234568 · retained source version 2026-11-13:a28e8c0c72340c2391372a337b792d7c366d254cc51271161d40f05c0ebc53db** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04234568) (`ctg-observation-nct04234568-2026-11-13-a28e8c0c7234`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04234568." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04234568-lutetium-lu-177-dotatate-v1 SHA-256: 03f7b97ceb713fd11f52135a31a86684782f1cd87292236a9848bc9902a617ba.

---

<a id="clinicaltrials-gov-nct04261855-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04261855

> PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04261855-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-03-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04261855-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04261855-lutetium-lu-177-dotatate-v1
- Content SHA-256: `7b00686ea026560fa8b55476ca35a7c1339d4f7669a2629e9e53bd794f106707`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04261855 ([`ctg-observation-nct04261855-2026-03-27-0b227b4ddf34`](#source-ctg-observation-nct04261855-2026-03-27-0b227b4ddf34))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04261855-2026-03-27-0b227b4ddf34`](#source-ctg-observation-nct04261855-2026-03-27-0b227b4ddf34))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04261855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-03-27, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04261855-2026-03-27-0b227b4ddf34`](#source-ctg-observation-nct04261855-2026-03-27-0b227b4ddf34))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04261855-2026-03-27-0b227b4ddf34`](#source-ctg-observation-nct04261855-2026-03-27-0b227b4ddf34))

### Sources

<a id="source-ctg-observation-nct04261855-2026-03-27-0b227b4ddf34"></a>
- **ClinicalTrials.gov record NCT04261855 · retained source version 2026-03-27:0b227b4ddf34f7bc44083b27df67fbec8d893597ea09355a798e4643e7636d70** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04261855) (`ctg-observation-nct04261855-2026-03-27-0b227b4ddf34`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04261855." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04261855-lutetium-lu-177-dotatate-v1 SHA-256: 7b00686ea026560fa8b55476ca35a7c1339d4f7669a2629e9e53bd794f106707.

---

<a id="clinicaltrials-gov-nct04529044-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04529044

> PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04529044-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-05
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04529044-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04529044-lutetium-lu-177-dotatate-v1
- Content SHA-256: `d9862ffa86699343c8205f6c8f64c3e3bbd0d33bea3a5b9de3461485b72cf48c`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04529044 ([`ctg-observation-nct04529044-2026-06-05-c349cd12c873`](#source-ctg-observation-nct04529044-2026-06-05-c349cd12c873))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04529044-2026-06-05-c349cd12c873`](#source-ctg-observation-nct04529044-2026-06-05-c349cd12c873))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04529044 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-05, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04529044-2026-06-05-c349cd12c873`](#source-ctg-observation-nct04529044-2026-06-05-c349cd12c873))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04529044-2026-06-05-c349cd12c873`](#source-ctg-observation-nct04529044-2026-06-05-c349cd12c873))

### Sources

<a id="source-ctg-observation-nct04529044-2026-06-05-c349cd12c873"></a>
- **ClinicalTrials.gov record NCT04529044 · retained source version 2026-06-05:c349cd12c8732d05f7a0b829a6a60163cab70a2dc5f188c0fcda67e1f77eff5c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04529044) (`ctg-observation-nct04529044-2026-06-05-c349cd12c873`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04529044." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04529044-lutetium-lu-177-dotatate-v1 SHA-256: d9862ffa86699343c8205f6c8f64c3e3bbd0d33bea3a5b9de3461485b72cf48c.

---

<a id="clinicaltrials-gov-nct04665739-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04665739

> PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04665739-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04665739-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04665739-lutetium-lu-177-dotatate-v1
- Content SHA-256: `a6ab7a33e782b39bd19beea391d5e4c0257b7f129d3c3adc6e68f0ffc24b9486`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04665739 ([`ctg-observation-nct04665739-2026-11-12-535c6253efb9`](#source-ctg-observation-nct04665739-2026-11-12-535c6253efb9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04665739-2026-11-12-535c6253efb9`](#source-ctg-observation-nct04665739-2026-11-12-535c6253efb9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04665739 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04665739-2026-11-12-535c6253efb9`](#source-ctg-observation-nct04665739-2026-11-12-535c6253efb9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04665739-2026-11-12-535c6253efb9`](#source-ctg-observation-nct04665739-2026-11-12-535c6253efb9))

### Sources

<a id="source-ctg-observation-nct04665739-2026-11-12-535c6253efb9"></a>
- **ClinicalTrials.gov record NCT04665739 · retained source version 2026-11-12:535c6253efb952b8dbf1cae134d8cf15a1f05671c87ba4a03c962227ccd940aa** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04665739) (`ctg-observation-nct04665739-2026-11-12-535c6253efb9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04665739." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04665739-lutetium-lu-177-dotatate-v1 SHA-256: a6ab7a33e782b39bd19beea391d5e4c0257b7f129d3c3adc6e68f0ffc24b9486.

---

<a id="clinicaltrials-gov-nct04711135-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04711135

> PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04711135-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-02-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04711135-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04711135-lutetium-lu-177-dotatate-v1
- Content SHA-256: `a3bf918a08e49f039507f85fbb41aad576613c6f69d6b7f67b9e9f88a9b72a63`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04711135 ([`ctg-observation-nct04711135-2026-02-12-785e10919588`](#source-ctg-observation-nct04711135-2026-02-12-785e10919588))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04711135-2026-02-12-785e10919588`](#source-ctg-observation-nct04711135-2026-02-12-785e10919588))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04711135 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-02-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04711135-2026-02-12-785e10919588`](#source-ctg-observation-nct04711135-2026-02-12-785e10919588))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04711135-2026-02-12-785e10919588`](#source-ctg-observation-nct04711135-2026-02-12-785e10919588))

### Sources

<a id="source-ctg-observation-nct04711135-2026-02-12-785e10919588"></a>
- **ClinicalTrials.gov record NCT04711135 · retained source version 2026-02-12:785e10919588b85cac5ae51484e8f821f825eab51089ece462a5a722866fa320** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04711135) (`ctg-observation-nct04711135-2026-02-12-785e10919588`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04711135." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04711135-lutetium-lu-177-dotatate-v1 SHA-256: a3bf918a08e49f039507f85fbb41aad576613c6f69d6b7f67b9e9f88a9b72a63.

---

<a id="clinicaltrials-gov-nct04750954-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04750954

> PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04750954-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04750954-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04750954-lutetium-lu-177-dotatate-v1
- Content SHA-256: `a3ea9b0ad77e380adec099d21b2b92bb2013fb1cd184e13fb82a9bcf01050da1`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04750954 ([`ctg-observation-nct04750954-2026-11-12-c58a98a87aaa`](#source-ctg-observation-nct04750954-2026-11-12-c58a98a87aaa))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04750954-2026-11-12-c58a98a87aaa`](#source-ctg-observation-nct04750954-2026-11-12-c58a98a87aaa))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04750954 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04750954-2026-11-12-c58a98a87aaa`](#source-ctg-observation-nct04750954-2026-11-12-c58a98a87aaa))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04750954-2026-11-12-c58a98a87aaa`](#source-ctg-observation-nct04750954-2026-11-12-c58a98a87aaa))

### Sources

<a id="source-ctg-observation-nct04750954-2026-11-12-c58a98a87aaa"></a>
- **ClinicalTrials.gov record NCT04750954 · retained source version 2026-11-12:c58a98a87aaa934948b5bfcdb080b3e93017e0b71d440c6ac8c03b9637b80546** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04750954) (`ctg-observation-nct04750954-2026-11-12-c58a98a87aaa`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04750954." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04750954-lutetium-lu-177-dotatate-v1 SHA-256: a3ea9b0ad77e380adec099d21b2b92bb2013fb1cd184e13fb82a9bcf01050da1.

---

<a id="clinicaltrials-gov-nct04954820-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT04954820

> PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct04954820-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-04
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct04954820-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04954820-lutetium-lu-177-dotatate-v1
- Content SHA-256: `d02a5992f1862f1d778b1b7bff78b2e0744030ff727ff0dc50ef23e945062d6f`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT04954820 ([`ctg-observation-nct04954820-2026-06-04-cf722a4cff59`](#source-ctg-observation-nct04954820-2026-06-04-cf722a4cff59))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04954820-2026-06-04-cf722a4cff59`](#source-ctg-observation-nct04954820-2026-06-04-cf722a4cff59))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT04954820 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-04, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct04954820-2026-06-04-cf722a4cff59`](#source-ctg-observation-nct04954820-2026-06-04-cf722a4cff59))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct04954820-2026-06-04-cf722a4cff59`](#source-ctg-observation-nct04954820-2026-06-04-cf722a4cff59))

### Sources

<a id="source-ctg-observation-nct04954820-2026-06-04-cf722a4cff59"></a>
- **ClinicalTrials.gov record NCT04954820 · retained source version 2026-06-04:cf722a4cff59c6e18a819423fd5d0d4118d33242926c159ed8e5d742156b194a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT04954820) (`ctg-observation-nct04954820-2026-06-04-cf722a4cff59`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT04954820." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct04954820-lutetium-lu-177-dotatate-v1 SHA-256: d02a5992f1862f1d778b1b7bff78b2e0744030ff727ff0dc50ef23e945062d6f.

---

<a id="clinicaltrials-gov-nct05142696-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05142696

> PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05142696-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-08-19
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05142696-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05142696-lutetium-lu-177-dotatate-v1
- Content SHA-256: `91a68d98213f69ed381ead55094660c5af20304e691d94cdb64bd0e01bc1ee78`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05142696 ([`ctg-observation-nct05142696-2026-08-19-8486a5958164`](#source-ctg-observation-nct05142696-2026-08-19-8486a5958164))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05142696-2026-08-19-8486a5958164`](#source-ctg-observation-nct05142696-2026-08-19-8486a5958164))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05142696 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-08-19, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05142696-2026-08-19-8486a5958164`](#source-ctg-observation-nct05142696-2026-08-19-8486a5958164))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05142696-2026-08-19-8486a5958164`](#source-ctg-observation-nct05142696-2026-08-19-8486a5958164))

### Sources

<a id="source-ctg-observation-nct05142696-2026-08-19-8486a5958164"></a>
- **ClinicalTrials.gov record NCT05142696 · retained source version 2026-08-19:8486a595816473e38b13fbef924c263c64110dd9a10a7bc6d195a0f04a912ef3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05142696) (`ctg-observation-nct05142696-2026-08-19-8486a5958164`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05142696." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05142696-lutetium-lu-177-dotatate-v1 SHA-256: 91a68d98213f69ed381ead55094660c5af20304e691d94cdb64bd0e01bc1ee78.

---

<a id="clinicaltrials-gov-nct05178693-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05178693

> PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05178693-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05178693-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05178693-lutetium-lu-177-dotatate-v1
- Content SHA-256: `4d6f95c9de677f9faee0c3cf8eca5c27e0a7dcc20fa0daaa566d639a3282fd08`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05178693 ([`ctg-observation-nct05178693-2026-11-12-3374f833f0ec`](#source-ctg-observation-nct05178693-2026-11-12-3374f833f0ec))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05178693-2026-11-12-3374f833f0ec`](#source-ctg-observation-nct05178693-2026-11-12-3374f833f0ec))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05178693 at 2026-11-16T02:15:32.969Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05178693-2026-11-12-3374f833f0ec`](#source-ctg-observation-nct05178693-2026-11-12-3374f833f0ec))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05178693-2026-11-12-3374f833f0ec`](#source-ctg-observation-nct05178693-2026-11-12-3374f833f0ec))

### Sources

<a id="source-ctg-observation-nct05178693-2026-11-12-3374f833f0ec"></a>
- **ClinicalTrials.gov record NCT05178693 · retained source version 2026-11-12:3374f833f0ecaa29e992a5825ae02f12ce273422248f1af3c468c3da790114dd** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05178693) (`ctg-observation-nct05178693-2026-11-12-3374f833f0ec`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05178693." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05178693-lutetium-lu-177-dotatate-v1 SHA-256: 4d6f95c9de677f9faee0c3cf8eca5c27e0a7dcc20fa0daaa566d639a3282fd08.

---

<a id="clinicaltrials-gov-nct05247905-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05247905

> PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05247905-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-10-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05247905-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05247905-lutetium-lu-177-dotatate-v1
- Content SHA-256: `5b65cc718b3ceb2a6e127e18d0831989132b176efea3741d84d02223adf211fb`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05247905 ([`ctg-observation-nct05247905-2026-10-20-94a24b6df17d`](#source-ctg-observation-nct05247905-2026-10-20-94a24b6df17d))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05247905-2026-10-20-94a24b6df17d`](#source-ctg-observation-nct05247905-2026-10-20-94a24b6df17d))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05247905 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-10-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05247905-2026-10-20-94a24b6df17d`](#source-ctg-observation-nct05247905-2026-10-20-94a24b6df17d))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05247905-2026-10-20-94a24b6df17d`](#source-ctg-observation-nct05247905-2026-10-20-94a24b6df17d))

### Sources

<a id="source-ctg-observation-nct05247905-2026-10-20-94a24b6df17d"></a>
- **ClinicalTrials.gov record NCT05247905 · retained source version 2026-10-20:94a24b6df17d44fc1f296e4af3702ca86a03dd75ead6b88dd6a23f82d2ff734f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05247905) (`ctg-observation-nct05247905-2026-10-20-94a24b6df17d`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05247905." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05247905-lutetium-lu-177-dotatate-v1 SHA-256: 5b65cc718b3ceb2a6e127e18d0831989132b176efea3741d84d02223adf211fb.

---

<a id="clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05278208

> PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v1
- Content SHA-256: `33a18607f42d9e28c7f1c0433ef98417d97732b5a6bf6be77a28880b4697cc11`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05278208 ([`ctg-observation-nct05278208-2026-07-20-294c4af79959`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-20, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959))

### Sources

<a id="source-ctg-observation-nct05278208-2026-07-20-294c4af79959"></a>
- **ClinicalTrials.gov record NCT05278208 · retained source version 2026-07-20:294c4af79959329830dc5ea81fea4063c09a422cdae1f5c4f7ebff8eeeae424f** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05278208) (`ctg-observation-nct05278208-2026-07-20-294c4af79959`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05278208." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v1 SHA-256: 33a18607f42d9e28c7f1c0433ef98417d97732b5a6bf6be77a28880b4697cc11.

---

<a id="clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v2"></a>

## ClinicalTrials.gov record NCT05278208

> PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate:v2`
- Evidence domain: Clinical trials
- Date in source: 2026-11-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v2
- Content SHA-256: `105166659cd5e2bd44bc9153a261e1004317e5fd766e25ad62e12bbf2b8b5f23`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05278208 ([`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05278208 at 2026-11-16T13:28:59.838Z. Its registry update date was 2026-11-16, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2))

### Sources

<a id="source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2"></a>
- **ClinicalTrials.gov record NCT05278208 · retained source version 2026-11-16:516842d0ad86c0b81b029177e9786f5f7ea463f2778ec86219d6cae0e7ac5d5c** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05278208) (`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`)

### Correction lineage

updated on 2026-11-16: ClinicalTrials.gov posted a newer version of NCT05278208, with a registry update date of 2026-11-16. This version reports that observation; the earlier retained observation remains available as version 1.
- Supersedes version: 1
- Correction sources: [`ctg-observation-nct05278208-2026-07-20-294c4af79959-r2`](#source-ctg-observation-nct05278208-2026-07-20-294c4af79959-r2)

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05278208." Version 2, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05278208-lutetium-lu-177-dotatate-v2 SHA-256: 105166659cd5e2bd44bc9153a261e1004317e5fd766e25ad62e12bbf2b8b5f23.

---

<a id="clinicaltrials-gov-nct05583708-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05583708

> PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05583708-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-09-25
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05583708-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05583708-lutetium-lu-177-dotatate-v1
- Content SHA-256: `179cecede0d55b4b7c5349bbc91c3621fc943033d558e32421dcab2b9fb12474`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05583708 ([`ctg-observation-nct05583708-2026-09-25-c8193ee79944`](#source-ctg-observation-nct05583708-2026-09-25-c8193ee79944))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05583708-2026-09-25-c8193ee79944`](#source-ctg-observation-nct05583708-2026-09-25-c8193ee79944))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05583708 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-09-25, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05583708-2026-09-25-c8193ee79944`](#source-ctg-observation-nct05583708-2026-09-25-c8193ee79944))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05583708-2026-09-25-c8193ee79944`](#source-ctg-observation-nct05583708-2026-09-25-c8193ee79944))

### Sources

<a id="source-ctg-observation-nct05583708-2026-09-25-c8193ee79944"></a>
- **ClinicalTrials.gov record NCT05583708 · retained source version 2026-09-25:c8193ee79944e5af05f400f8550485c28bf08e96928e7605ef85d55137d4233a** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05583708) (`ctg-observation-nct05583708-2026-09-25-c8193ee79944`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05583708." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05583708-lutetium-lu-177-dotatate-v1 SHA-256: 179cecede0d55b4b7c5349bbc91c3621fc943033d558e32421dcab2b9fb12474.

---

<a id="clinicaltrials-gov-nct05691465-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05691465

> PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05691465-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05691465-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05691465-lutetium-lu-177-dotatate-v1
- Content SHA-256: `1eaaf2c337d74e826e39472d2d112a216d990d8423c32b5fc008d04821c3cb24`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05691465 ([`ctg-observation-nct05691465-2026-11-12-4b2a5083cc36`](#source-ctg-observation-nct05691465-2026-11-12-4b2a5083cc36))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05691465-2026-11-12-4b2a5083cc36`](#source-ctg-observation-nct05691465-2026-11-12-4b2a5083cc36))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05691465 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05691465-2026-11-12-4b2a5083cc36`](#source-ctg-observation-nct05691465-2026-11-12-4b2a5083cc36))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05691465-2026-11-12-4b2a5083cc36`](#source-ctg-observation-nct05691465-2026-11-12-4b2a5083cc36))

### Sources

<a id="source-ctg-observation-nct05691465-2026-11-12-4b2a5083cc36"></a>
- **ClinicalTrials.gov record NCT05691465 · retained source version 2026-11-12:4b2a5083cc36db322b43d64c8f43d35d4e8d44a85a2a53d34db988baa219d84b** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05691465) (`ctg-observation-nct05691465-2026-11-12-4b2a5083cc36`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05691465." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05691465-lutetium-lu-177-dotatate-v1 SHA-256: 1eaaf2c337d74e826e39472d2d112a216d990d8423c32b5fc008d04821c3cb24.

---

<a id="clinicaltrials-gov-nct05724108-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05724108

> PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05724108-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-07-31
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05724108-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05724108-lutetium-lu-177-dotatate-v1
- Content SHA-256: `5b747ceb193071ef0fc3b462c45bea3016b877b7f9eb995e4a3aed4032dafbab`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05724108 ([`ctg-observation-nct05724108-2026-07-31-c280ba29ef60`](#source-ctg-observation-nct05724108-2026-07-31-c280ba29ef60))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05724108-2026-07-31-c280ba29ef60`](#source-ctg-observation-nct05724108-2026-07-31-c280ba29ef60))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05724108 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-07-31, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05724108-2026-07-31-c280ba29ef60`](#source-ctg-observation-nct05724108-2026-07-31-c280ba29ef60))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05724108-2026-07-31-c280ba29ef60`](#source-ctg-observation-nct05724108-2026-07-31-c280ba29ef60))

### Sources

<a id="source-ctg-observation-nct05724108-2026-07-31-c280ba29ef60"></a>
- **ClinicalTrials.gov record NCT05724108 · retained source version 2026-07-31:c280ba29ef60a9eae65a971d4cbc4d9af473947bc27a5f6d039242e70d57c436** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05724108) (`ctg-observation-nct05724108-2026-07-31-c280ba29ef60`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05724108." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05724108-lutetium-lu-177-dotatate-v1 SHA-256: 5b747ceb193071ef0fc3b462c45bea3016b877b7f9eb995e4a3aed4032dafbab.

---

<a id="clinicaltrials-gov-nct05773274-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT05773274

> PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct05773274-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-12
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct05773274-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05773274-lutetium-lu-177-dotatate-v1
- Content SHA-256: `b567050e99e699dae51f707945e5edade806239dbc99625cac105703c8eb6a45`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT05773274 ([`ctg-observation-nct05773274-2026-11-12-36896c465877`](#source-ctg-observation-nct05773274-2026-11-12-36896c465877))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05773274-2026-11-12-36896c465877`](#source-ctg-observation-nct05773274-2026-11-12-36896c465877))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT05773274 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-12, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct05773274-2026-11-12-36896c465877`](#source-ctg-observation-nct05773274-2026-11-12-36896c465877))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct05773274-2026-11-12-36896c465877`](#source-ctg-observation-nct05773274-2026-11-12-36896c465877))

### Sources

<a id="source-ctg-observation-nct05773274-2026-11-12-36896c465877"></a>
- **ClinicalTrials.gov record NCT05773274 · retained source version 2026-11-12:36896c4658771c20585f08499518cc8db1730850735bed1d4758f3d49644e8ef** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT05773274) (`ctg-observation-nct05773274-2026-11-12-36896c465877`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT05773274." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct05773274-lutetium-lu-177-dotatate-v1 SHA-256: b567050e99e699dae51f707945e5edade806239dbc99625cac105703c8eb6a45.

---

<a id="clinicaltrials-gov-nct06016855-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT06016855

> PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct06016855-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-24
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06016855-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06016855-lutetium-lu-177-dotatate-v1
- Content SHA-256: `bf8f8d42858e72082c24145237d2f922a9127ad8c0bc233be51da5bffa676644`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06016855 ([`ctg-observation-nct06016855-2026-06-24-e00558e15eef`](#source-ctg-observation-nct06016855-2026-06-24-e00558e15eef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06016855-2026-06-24-e00558e15eef`](#source-ctg-observation-nct06016855-2026-06-24-e00558e15eef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06016855 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-24, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06016855-2026-06-24-e00558e15eef`](#source-ctg-observation-nct06016855-2026-06-24-e00558e15eef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06016855-2026-06-24-e00558e15eef`](#source-ctg-observation-nct06016855-2026-06-24-e00558e15eef))

### Sources

<a id="source-ctg-observation-nct06016855-2026-06-24-e00558e15eef"></a>
- **ClinicalTrials.gov record NCT06016855 · retained source version 2026-06-24:e00558e15eefe560c8d8674053f0abfa0158698bdcbf66b5a7ba1f8b3c5671de** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06016855) (`ctg-observation-nct06016855-2026-06-24-e00558e15eef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06016855." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06016855-lutetium-lu-177-dotatate-v1 SHA-256: bf8f8d42858e72082c24145237d2f922a9127ad8c0bc233be51da5bffa676644.

---

<a id="clinicaltrials-gov-nct06326190-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT06326190

> PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct06326190-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-06-15
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06326190-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06326190-lutetium-lu-177-dotatate-v1
- Content SHA-256: `2958a72fa15e9f2574356c02a447d53382b2e87855ff82263225971d73780662`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06326190 ([`ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9`](#source-ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9`](#source-ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06326190 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-06-15, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9`](#source-ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9`](#source-ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9))

### Sources

<a id="source-ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9"></a>
- **ClinicalTrials.gov record NCT06326190 · retained source version 2026-06-15:f06c3b0a9ca94b5ca2e8c41a6c84bfd7c6927a1e47c4a0ae3fd15c2fa44b97ee** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06326190) (`ctg-observation-nct06326190-2026-06-15-f06c3b0a9ca9`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06326190." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06326190-lutetium-lu-177-dotatate-v1 SHA-256: 2958a72fa15e9f2574356c02a447d53382b2e87855ff82263225971d73780662.

---

<a id="clinicaltrials-gov-nct06395402-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT06395402

> PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct06395402-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2025-07-22
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06395402-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06395402-lutetium-lu-177-dotatate-v1
- Content SHA-256: `83d45435a12ec6f27d3c5c7187dcce7546ee6607821e82ff6057a47d2340c6e7`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06395402 ([`ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5`](#source-ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5`](#source-ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06395402 at 2026-11-16T01:36:36.861Z. Its registry update date was 2025-07-22, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5`](#source-ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5`](#source-ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5))

### Sources

<a id="source-ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5"></a>
- **ClinicalTrials.gov record NCT06395402 · retained source version 2025-07-22:a4cbd4c253f590f9c7a460cab1d8cf4d066643978266ade50a191d8b5a4900bc** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06395402) (`ctg-observation-nct06395402-2025-07-22-a4cbd4c253f5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06395402." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06395402-lutetium-lu-177-dotatate-v1 SHA-256: 83d45435a12ec6f27d3c5c7187dcce7546ee6607821e82ff6057a47d2340c6e7.

---

<a id="clinicaltrials-gov-nct06955169-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT06955169

> PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct06955169-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct06955169-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06955169-lutetium-lu-177-dotatate-v1
- Content SHA-256: `766b17e8a800340a208a8644d1b5667bed06ebaad1b83d03f363b078be466b9a`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT06955169 ([`ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b`](#source-ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b`](#source-ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT06955169 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-09, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b`](#source-ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b`](#source-ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b))

### Sources

<a id="source-ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b"></a>
- **ClinicalTrials.gov record NCT06955169 · retained source version 2026-11-09:0c400fe7fb6b1de0771b4016d0432305e5343fb68568177ffc834c63e45f99f3** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT06955169) (`ctg-observation-nct06955169-2026-11-09-0c400fe7fb6b`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT06955169." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct06955169-lutetium-lu-177-dotatate-v1 SHA-256: 766b17e8a800340a208a8644d1b5667bed06ebaad1b83d03f363b078be466b9a.

---

<a id="clinicaltrials-gov-nct07910760-lutetium-lu-177-dotatate-v1"></a>

## ClinicalTrials.gov record NCT07910760

> PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate.

- Evidence object: `story:clinicaltrials-gov-nct07910760-lutetium-lu-177-dotatate:v1`
- Evidence domain: Clinical trials
- Date in source: 2026-11-02
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/clinicaltrials-gov-nct07910760-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct07910760-lutetium-lu-177-dotatate-v1
- Content SHA-256: `7695d12ce55245a6d86e5ea73f0c3cfca11ed06fe19223f9fc80bbe1dce4f6f3`

### Claims and source pins

#### Headline

ClinicalTrials.gov record NCT07910760 ([`ctg-observation-nct07910760-2026-11-02-a67ce61aeeef`](#source-ctg-observation-nct07910760-2026-11-02-a67ce61aeeef))

#### Summary

PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct07910760-2026-11-02-a67ce61aeeef`](#source-ctg-observation-nct07910760-2026-11-02-a67ce61aeeef))

#### Paragraph 1

PeptideScanner retained ClinicalTrials.gov record NCT07910760 at 2026-11-16T01:36:36.861Z. Its registry update date was 2026-11-02, and PeptideScanner's reviewed identity mapping was lutetium-lu-177-dotatate. ([`ctg-observation-nct07910760-2026-11-02-a67ce61aeeef`](#source-ctg-observation-nct07910760-2026-11-02-a67ce61aeeef))

#### Paragraph 2

This page reports a dated retained registry observation and does not assert the record's current status; registration is not evidence that an intervention is safe or effective. ([`ctg-observation-nct07910760-2026-11-02-a67ce61aeeef`](#source-ctg-observation-nct07910760-2026-11-02-a67ce61aeeef))

### Sources

<a id="source-ctg-observation-nct07910760-2026-11-02-a67ce61aeeef"></a>
- **ClinicalTrials.gov record NCT07910760 · retained source version 2026-11-02:a67ce61aeeef8c6787ab5ca54484cad5155c22c1fcddf3af1c422a499c560e36** — ClinicalTrials.gov; class A. [Open source](https://clinicaltrials.gov/study/NCT07910760) (`ctg-observation-nct07910760-2026-11-02-a67ce61aeeef`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited trial-registry entry and its status at observation. Registration or completion does not establish safety, effectiveness, or regulatory approval.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "ClinicalTrials.gov record NCT07910760." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#clinicaltrials-gov-nct07910760-lutetium-lu-177-dotatate-v1 SHA-256: 7695d12ce55245a6d86e5ea73f0c3cfca11ed06fe19223f9fc80bbe1dce4f6f3.

---

<a id="fda-drugs-anda217060-v1"></a>

## Drugs@FDA application ANDA217060

> The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-anda217060:v1`
- Evidence domain: Regulatory
- Date in source: 2026-09-21
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-anda217060/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-anda217060-v1
- Content SHA-256: `319cf58d033fb0a5167de7b48993c7eaeb59ceaa32e08fa084d3ea19fc3a6d94`

### Claims and source pins

#### Headline

Drugs@FDA application ANDA217060 ([`fda-drugs-anda217060-2026-09-21-9873e80de062`](#source-fda-drugs-anda217060-2026-09-21-9873e80de062))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-anda217060-2026-09-21-9873e80de062`](#source-fda-drugs-anda217060-2026-09-21-9873e80de062))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for ANDA 217060 with status AP dated 2026-09-21, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-anda217060-2026-09-21-9873e80de062`](#source-fda-drugs-anda217060-2026-09-21-9873e80de062))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-anda217060-2026-09-21-9873e80de062`](#source-fda-drugs-anda217060-2026-09-21-9873e80de062))

### Sources

<a id="source-fda-drugs-anda217060-2026-09-21-9873e80de062"></a>
- **Drugs@FDA application ANDA217060 · original submission status AP · 2026-09-21 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22ANDA217060%22&limit=1) (`fda-drugs-anda217060-2026-09-21-9873e80de062`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application ANDA217060." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-anda217060-v1 SHA-256: 319cf58d033fb0a5167de7b48993c7eaeb59ceaa32e08fa084d3ea19fc3a6d94.

---

<a id="fda-drugs-nda208700-v1"></a>

## Drugs@FDA application NDA208700

> The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda208700:v1`
- Evidence domain: Regulatory
- Date in source: 2018-01-26
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda208700/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-nda208700-v1
- Content SHA-256: `b482a4eb341ca2787d9574d82ba77a908df85aee20af54a89f54014b84d11c96`

### Claims and source pins

#### Headline

Drugs@FDA application NDA208700 ([`fda-drugs-nda208700-2018-01-26-fa58be5f33e6`](#source-fda-drugs-nda208700-2018-01-26-fa58be5f33e6))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-nda208700-2018-01-26-fa58be5f33e6`](#source-fda-drugs-nda208700-2018-01-26-fa58be5f33e6))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 208700 with status AP dated 2018-01-26, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-nda208700-2018-01-26-fa58be5f33e6`](#source-fda-drugs-nda208700-2018-01-26-fa58be5f33e6))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda208700-2018-01-26-fa58be5f33e6`](#source-fda-drugs-nda208700-2018-01-26-fa58be5f33e6))

### Sources

<a id="source-fda-drugs-nda208700-2018-01-26-fa58be5f33e6"></a>
- **Drugs@FDA application NDA208700 · original submission status AP · 2018-01-26 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA208700%22&limit=1) (`fda-drugs-nda208700-2018-01-26-fa58be5f33e6`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA208700." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-nda208700-v1 SHA-256: b482a4eb341ca2787d9574d82ba77a908df85aee20af54a89f54014b84d11c96.

---

<a id="fda-drugs-nda218525-v1"></a>

## Drugs@FDA application NDA218525

> The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients.

- Evidence object: `story:fda-drugs-nda218525:v1`
- Evidence domain: Regulatory
- Date in source: 2026-09-14
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/fda-drugs-nda218525/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-nda218525-v1
- Content SHA-256: `7eb99705fb779947d31b408ea9eac985dfd850b428d57966cd10e5c2901e4539`

### Claims and source pins

#### Headline

Drugs@FDA application NDA218525 ([`fda-drugs-nda218525-2026-09-14-fdd38718ee13`](#source-fda-drugs-nda218525-2026-09-14-fdd38718ee13))

#### Summary

The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-nda218525-2026-09-14-fdd38718ee13`](#source-fda-drugs-nda218525-2026-09-14-fdd38718ee13))

#### Paragraph 1

The official Drugs@FDA dataset lists original submission 1 for NDA 218525 with status AP dated 2026-09-14, and names lutetium lu-177 dotatate among the application record's active ingredients. ([`fda-drugs-nda218525-2026-09-14-fdd38718ee13`](#source-fda-drugs-nda218525-2026-09-14-fdd38718ee13))

#### Paragraph 2

This page reports bounded application metadata attributed to Drugs@FDA. It does not reproduce labeling, describe an indication, compare products, or provide medical guidance. ([`fda-drugs-nda218525-2026-09-14-fdd38718ee13`](#source-fda-drugs-nda218525-2026-09-14-fdd38718ee13))

### Sources

<a id="source-fda-drugs-nda218525-2026-09-14-fdd38718ee13"></a>
- **Drugs@FDA application NDA218525 · original submission status AP · 2026-09-14 · dataset 2026-11-13** — Drugs@FDA via openFDA; class A. [Open source](https://api.fda.gov/drug/drugsfda.json?search=application_number%3A%22NDA218525%22&limit=1) (`fda-drugs-nda218525-2026-09-14-fdd38718ee13`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Drugs@FDA application NDA218525." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#fda-drugs-nda218525-v1 SHA-256: 7eb99705fb779947d31b408ea9eac985dfd850b428d57966cd10e5c2901e4539.

---

<a id="federal-register-2022-25549-v1"></a>

## Federal Register notice 2022-25549

> The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate.

- Evidence object: `story:federal-register-2022-25549:v1`
- Evidence domain: Regulatory
- Date in source: 2022-11-23
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/federal-register-2022-25549/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#federal-register-2022-25549-v1
- Content SHA-256: `802bdda3df5ef329a6b277c81cee768bfee7dc2036497257e006da20ce90893a`

### Claims and source pins

#### Headline

Federal Register notice 2022-25549 ([`federal-register-2022-25549-0002fae93d1e`](#source-federal-register-2022-25549-0002fae93d1e))

#### Summary

The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate. ([`federal-register-2022-25549-0002fae93d1e`](#source-federal-register-2022-25549-0002fae93d1e))

#### Paragraph 1

The Federal Register published notice 2022-25549, attributed to FDA and its parent HHS department, on 2022-11-23. Its official title is “List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” and PeptideScanner's exact reviewed identity mapping connects the document to Lutetium Lu 177 dotatate. ([`federal-register-2022-25549-0002fae93d1e`](#source-federal-register-2022-25549-0002fae93d1e))

#### Paragraph 2

This page reports bounded metadata from a Federal Register document attributed to FDA and its parent HHS department, and links to the official GovInfo PDF. It does not interpret legal effect, approval, safety, effectiveness, compounding status, or medical use. ([`federal-register-2022-25549-0002fae93d1e`](#source-federal-register-2022-25549-0002fae93d1e))

### Sources

<a id="source-federal-register-2022-25549-0002fae93d1e"></a>
- **Federal Register notice 2022-25549 · published 2022-11-23 · List of Bulk Drug Substances for Which There is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act** — Federal Register via GovInfo; class A. [Open source](https://www.govinfo.gov/content/pkg/FR-2022-11-23/pdf/2022-25549.pdf) (`federal-register-2022-25549-0002fae93d1e`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reports the cited regulator or label record. It does not extend that record into broader safety, effectiveness, or approval claims.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Federal Register notice 2022-25549." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#federal-register-2022-25549-v1 SHA-256: 802bdda3df5ef329a6b277c81cee768bfee7dc2036497257e006da20ce90893a.

---

<a id="pubmed-pmid-32616557-lutetium-lu-177-dotatate-v1"></a>

## Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung.

> PubMed lists PMID 32616557 in Journal for immunotherapy of cancer as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-07 (month precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-32616557-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2021-09-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-32616557-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-32616557-lutetium-lu-177-dotatate-v1
- Content SHA-256: `65625a0fe5473257ab4220e18ef809d52fba4dc16bdf5fe772708d3869df874f`

### Claims and source pins

#### Headline

Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. ([`pubmed-observation-pmid-32616557-2021-09-20-61036108e954`](#source-pubmed-observation-pmid-32616557-2021-09-20-61036108e954))

#### Summary

PubMed lists PMID 32616557 in Journal for immunotherapy of cancer as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-07 (month precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32616557-2021-09-20-61036108e954`](#source-pubmed-observation-pmid-32616557-2021-09-20-61036108e954))

#### Paragraph 1

PubMed lists PMID 32616557 in Journal for immunotherapy of cancer as Clinical Trial, Phase I, Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2020-07 (month precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-32616557-2021-09-20-61036108e954`](#source-pubmed-observation-pmid-32616557-2021-09-20-61036108e954))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-32616557-2021-09-20-61036108e954`](#source-pubmed-observation-pmid-32616557-2021-09-20-61036108e954))

### Sources

<a id="source-pubmed-observation-pmid-32616557-2021-09-20-61036108e954"></a>
- **Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung. · retained source version 1:2021-09-20:current:61036108e9549b8c2164811e1d2237d9b123300bcffc4d2a23ceb61dd27290b9** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/32616557/) (`pubmed-observation-pmid-32616557-2021-09-20-61036108e954`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-32616557-lutetium-lu-177-dotatate-v1 SHA-256: 65625a0fe5473257ab4220e18ef809d52fba4dc16bdf5fe772708d3869df874f.

---

<a id="pubmed-pmid-33490736-lutetium-lu-177-dotatate-v1"></a>

## Lutetium Lu-177 Dotatate Flare Reaction.

> PubMed lists PMID 33490736 in Advances in radiation oncology as Journal Article, with publication-date metadata of 2020-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-33490736-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2022-04-20
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-33490736-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-33490736-lutetium-lu-177-dotatate-v1
- Content SHA-256: `3d000e9b7bdaee1c1f7e6d1ab8e5fa9dfca9254c85ad18dca207314e29c4ce69`

### Claims and source pins

#### Headline

Lutetium Lu-177 Dotatate Flare Reaction. ([`pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f`](#source-pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f))

#### Summary

PubMed lists PMID 33490736 in Advances in radiation oncology as Journal Article, with publication-date metadata of 2020-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f`](#source-pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f))

#### Paragraph 1

PubMed lists PMID 33490736 in Advances in radiation oncology as Journal Article, with publication-date metadata of 2020-11-26 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f`](#source-pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f`](#source-pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f))

### Sources

<a id="source-pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f"></a>
- **Lutetium Lu-177 Dotatate Flare Reaction. · retained source version 1:2022-04-20:current:a66ee0ceca5f47094427b919656a66ade7b16f16efa162862eb7627413d2cfbe** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/33490736/) (`pubmed-observation-pmid-33490736-2022-04-20-a66ee0ceca5f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lutetium Lu-177 Dotatate Flare Reaction." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-33490736-lutetium-lu-177-dotatate-v1 SHA-256: 3d000e9b7bdaee1c1f7e6d1ab8e5fa9dfca9254c85ad18dca207314e29c4ce69.

---

<a id="pubmed-pmid-36550428-lutetium-lu-177-dotatate-v1"></a>

## A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH).

> PubMed lists PMID 36550428 in BMC cancer as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2022-12-22 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-36550428-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-01-27
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-36550428-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-36550428-lutetium-lu-177-dotatate-v1
- Content SHA-256: `219b7cd117ca6e5105d196e69998d18dd6cd3c5fc44ce5b5d3cd9e2b057e813b`

### Claims and source pins

#### Headline

A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). ([`pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee`](#source-pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee))

#### Summary

PubMed lists PMID 36550428 in BMC cancer as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2022-12-22 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee`](#source-pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee))

#### Paragraph 1

PubMed lists PMID 36550428 in BMC cancer as Randomized Controlled Trial, Multicenter Study, Clinical Trial, Phase II, Journal Article, with publication-date metadata of 2022-12-22 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee`](#source-pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee`](#source-pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee))

### Sources

<a id="source-pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee"></a>
- **A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH). · retained source version 1:2026-01-27:current:ba58628c0beef757f4e4825a52f77867ffc52d264d030e3ed88a2aca67ecfdc0** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/36550428/) (`pubmed-observation-pmid-36550428-2026-01-27-ba58628c0bee`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "A prospective, randomized, phase II study to assess the schemas of retreatment with Lutathera® in patients with new progression of an intestinal, well-differentiated neuroendocrine tumor (ReLUTH)." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-36550428-lutetium-lu-177-dotatate-v1 SHA-256: 219b7cd117ca6e5105d196e69998d18dd6cd3c5fc44ce5b5d3cd9e2b057e813b.

---

<a id="pubmed-pmid-37111596-lutetium-lu-177-dotatate-v1"></a>

## Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE.

> PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37111596-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-05-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37111596-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37111596-lutetium-lu-177-dotatate-v1
- Content SHA-256: `9eea1a71d076e0ef8fc249dc00891bc97459d088844fed602c6fba1208dcd94a`

### Claims and source pins

#### Headline

Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE. ([`pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc`](#source-pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc))

#### Summary

PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc`](#source-pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc))

#### Paragraph 1

PubMed lists PMID 37111596 in Pharmaceutics as Journal Article, Review, with publication-date metadata of 2023-03-31 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc`](#source-pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc`](#source-pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc))

### Sources

<a id="source-pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc"></a>
- **Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE. · retained source version 1:2023-05-01:current:e17df6fb84dca66021129e22ab56841e1c87c8fd77b9a27145c9b365002d05ca** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37111596/) (`pubmed-observation-pmid-37111596-2023-05-01-e17df6fb84dc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Lutathera® Orphans: State of the Art and Future Application of Radioligand Therapy with 177Lu-DOTATATE." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37111596-lutetium-lu-177-dotatate-v1 SHA-256: 9eea1a71d076e0ef8fc249dc00891bc97459d088844fed602c6fba1208dcd94a.

---

<a id="pubmed-pmid-37184824-lutetium-lu-177-dotatate-v1"></a>

## Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case.

> PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37184824-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37184824-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37184824-lutetium-lu-177-dotatate-v1
- Content SHA-256: `d3270b25450dd1af373c4c92ae7db00e1c9a5cc386be544d8840c2b530a3cff0`

### Claims and source pins

#### Headline

Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case. ([`pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc`](#source-pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc))

#### Summary

PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc`](#source-pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc))

#### Paragraph 1

PubMed lists PMID 37184824 in European journal of drug metabolism and pharmacokinetics as Journal Article, with publication-date metadata of 2023-05-15 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc`](#source-pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc`](#source-pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc))

### Sources

<a id="source-pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc"></a>
- **Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case. · retained source version 1:2026-11-09:current:2afbae074adcf84438d6321e4b44e4c10f0eb215bdf1255136a9c61680fa3bdf** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37184824/) (`pubmed-observation-pmid-37184824-2026-11-09-2afbae074adc`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Clinical Pharmacokinetics of Radiopharmaceuticals from SPECT/CT Image Acquisition by Contouring in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Lu-177 DOTATATE (Lutathera®) Case." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37184824-lutetium-lu-177-dotatate-v1 SHA-256: d3270b25450dd1af373c4c92ae7db00e1c9a5cc386be544d8840c2b530a3cff0.

---

<a id="pubmed-pmid-37883194-lutetium-lu-177-dotatate-v1"></a>

## 177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor.

> PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37883194-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-09
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37883194-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37883194-lutetium-lu-177-dotatate-v1
- Content SHA-256: `95a70db5432dba8e34e9e883c5b88e032dee6123339f9b1ed4216428b634e5cb`

### Claims and source pins

#### Headline

177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor. ([`pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143`](#source-pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143))

#### Summary

PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143`](#source-pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143))

#### Paragraph 1

PubMed lists PMID 37883194 in Clinical nuclear medicine as Case Reports, Journal Article, with publication-date metadata of 2023-10-23 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143`](#source-pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143`](#source-pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143))

### Sources

<a id="source-pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143"></a>
- **177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor. · retained source version 1:2026-11-09:current:2c5a2129914322b9eebe77cbd801ca14e4d2a98fc31cf4c20998d6eaa3b07c54** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37883194/) (`pubmed-observation-pmid-37883194-2026-11-09-2c5a21299143`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "177 Lu-DOTATATE (Lutathera) Therapy in 68 Ga-DOTATATE PET/CT-Negative Liver Metastases of a Neuroendocrine Tumor." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37883194-lutetium-lu-177-dotatate-v1 SHA-256: 95a70db5432dba8e34e9e883c5b88e032dee6123339f9b1ed4216428b634e5cb.

---

<a id="pubmed-pmid-37930495-lutetium-lu-177-dotatate-v1"></a>

## Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®.

> PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-37930495-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2023-11-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-37930495-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37930495-lutetium-lu-177-dotatate-v1
- Content SHA-256: `10a1b5e81315f3e0df0017808606111cbca7c4306f3564c1b40c1aef3e115eda`

### Claims and source pins

#### Headline

Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®. ([`pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99`](#source-pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99))

#### Summary

PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99`](#source-pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99))

#### Paragraph 1

PubMed lists PMID 37930495 in EJNMMI radiopharmacy and chemistry as Journal Article, with publication-date metadata of 2023-11-06 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99`](#source-pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99`](#source-pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99))

### Sources

<a id="source-pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99"></a>
- **Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®. · retained source version 1:2023-11-10:current:4e472b683c99457b9750aabbd30daee401ead3b5a5d92c8cab27cdb73d73868f** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/37930495/) (`pubmed-observation-pmid-37930495-2023-11-10-4e472b683c99`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Evaluation of the 177mLu-concentration in in-house produced 177Lu-radiopharmaceuticals and commercially available Lutathera®." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-37930495-lutetium-lu-177-dotatate-v1 SHA-256: 10a1b5e81315f3e0df0017808606111cbca7c4306f3564c1b40c1aef3e115eda.

---

<a id="pubmed-pmid-38451361-lutetium-lu-177-dotatate-v1"></a>

## Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis.

> PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38451361-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-11-01
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38451361-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-38451361-lutetium-lu-177-dotatate-v1
- Content SHA-256: `9e85ddd55ec01804f64a79f20aef0092111664f4f7d79f771a583c130c7a87ee`

### Claims and source pins

#### Headline

Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. ([`pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f`](#source-pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f))

#### Summary

PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f`](#source-pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f))

#### Paragraph 1

PubMed lists PMID 38451361 in Journal of neuro-oncology as Journal Article, with publication-date metadata of 2024-03-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f`](#source-pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f`](#source-pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f))

### Sources

<a id="source-pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f"></a>
- **Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis. · retained source version 1:2026-11-01:current:9e68429a4e2f7965d3767e6743f4b266a3794f8bce3aa764c83f997d33483b06** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38451361/) (`pubmed-observation-pmid-38451361-2026-11-01-9e68429a4e2f`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Peptide radionuclide radiation therapy with Lutathera in multirecurrent nonanaplastic meningiomas: antitumoral activity study by growth rate analysis." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-38451361-lutetium-lu-177-dotatate-v1 SHA-256: 9e85ddd55ec01804f64a79f20aef0092111664f4f7d79f771a583c130c7a87ee.

---

<a id="pubmed-pmid-38849643-lutetium-lu-177-dotatate-v1"></a>

## Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA.

> PubMed lists PMID 38849643 in Endocrine as Letter, with publication-date metadata of 2024-06-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-38849643-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-10-10
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-38849643-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-38849643-lutetium-lu-177-dotatate-v1
- Content SHA-256: `5824e0f26f84fd3fd1793b9dbb9b0a737131dcb3ce96c270d846f8d3e7dde19a`

### Claims and source pins

#### Headline

Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA. ([`pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df`](#source-pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df))

#### Summary

PubMed lists PMID 38849643 in Endocrine as Letter, with publication-date metadata of 2024-06-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df`](#source-pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df))

#### Paragraph 1

PubMed lists PMID 38849643 in Endocrine as Letter, with publication-date metadata of 2024-06-07 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df`](#source-pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df`](#source-pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df))

### Sources

<a id="source-pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df"></a>
- **Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA. · retained source version 1:2026-10-10:current:0ae4e357a0df8c462b789a6116dfb30ac9f087295c60b13d347dc8e644527c09** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/38849643/) (`pubmed-observation-pmid-38849643-2026-10-10-0ae4e357a0df`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "Hematological toxicities with Lutathera® for neuroendocrine neoplasms: post-marketing surveillance data from the US-FDA." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-38849643-lutetium-lu-177-dotatate-v1 SHA-256: 5824e0f26f84fd3fd1793b9dbb9b0a737131dcb3ce96c270d846f8d3e7dde19a.

---

<a id="pubmed-pmid-41935511-lutetium-lu-177-dotatate-v1"></a>

## FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto.

> PubMed lists PMID 41935511 in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.

- Evidence object: `story:pubmed-pmid-41935511-lutetium-lu-177-dotatate:v1`
- Evidence domain: Literature metadata
- Date in source: 2026-09-16
- Source checked: 2026-11-16
- Published by PeptideScanner: 2026-11-16
- Story landing page: https://peptidescanner.com/stories/pubmed-pmid-41935511-lutetium-lu-177-dotatate/
- JSON record: https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-41935511-lutetium-lu-177-dotatate-v1
- Content SHA-256: `960fdc9caa0bd79e17d6be7aa502ffc533e13fd4d407cadb4fb19c2642cdf05e`

### Claims and source pins

#### Headline

FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. ([`pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5`](#source-pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5))

#### Summary

PubMed lists PMID 41935511 in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5`](#source-pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5))

#### Paragraph 1

PubMed lists PMID 41935511 in Applied radiation and isotopes : including data, instrumentation and methods for use in agriculture, industry and medicine as Journal Article, Research Support, Non-U.S. Gov't, with publication-date metadata of 2026-04-01 (day precision). PeptideScanner associated the retained record with the identity slug lutetium-lu-177-dotatate. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings. ([`pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5`](#source-pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5))

#### Paragraph 2

This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth. ([`pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5`](#source-pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5))

### Sources

<a id="source-pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5"></a>
- **FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto. · retained source version 1:2026-09-16:current:073ef6cbbdb55cda9001b7136040ec6850baf34a147ea665958117e06017aa3d** — PubMed; class A. [Open source](https://pubmed.ncbi.nlm.nih.gov/41935511/) (`pubmed-observation-pmid-41935511-2026-09-16-073ef6cbbdb5`)

### Correction lineage

No correction is recorded for this version.

### Reporting boundaries and unknowns

PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.

- Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.
- This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.
- This object does not determine safety, efficacy, causality, or suitability for any person.

Methodology: https://peptidescanner.com/methodology/
Medical disclaimer: https://peptidescanner.com/medical-disclaimer/

### Suggested citation

PeptideScanner. "FAERS based pharmacovigilance study and network pharmacology analysis of Lutathera and Pluvicto." Version 1, published 2026-11-16. https://peptidescanner.com/evidence/v1/peptides/lutetium-lu-177-dotatate.json#pubmed-pmid-41935511-lutetium-lu-177-dotatate-v1 SHA-256: 960fdc9caa0bd79e17d6be7aa502ffc533e13fd4d407cadb4fb19c2642cdf05e.

